Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.

Investigation Reveals Deep Flaws in FDA Drug Approval Process, Raising Concerns Over Public Safety** A recent investigative report has uncovered alarming findings regarding the ...

Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly ...